Kanger ventures into manufacturing, sales of surgical face masks - MIDA | Malaysian Investment Development Authority
contrastBtngrayscaleBtn oku-icon


plusBtn crossBtn minusBtn


This site
is mobile


Kanger ventures into manufacturing, sales of surgical face masks

Kanger ventures into manufacturing, sales of surgical face masks

30 Aug 2021

Kanger International Bhd’s (KIB) wholly-owned subsidiary, Kanger Medical International Sdn Bhd (KMI) has ventured into the distribution and sale of high-quality 4-ply surgical face masks under the brand CommonMask.

The first range of CommonMask premium 4-ply surgical face masks are not only designed to provide better comfort and protection but also comes in four colours that allow their wearers to make a unique fashion statement.

The 4-ply configuration is designed to provide 99 per cent filtration efficiency against bacteria and other particles, while the hydrophobic outer layer protects the wearer from liquids droplets and biofluids.

KIB executive director Steven Kuah Choon Ching said the venture is in line with KIB’s aspirations to grow its new healthcare business, adding that the masks are also crafted with super materials that are gentle on the skin.

“Consumers are becoming increasingly conscious of the quality of their protection from the highly contagious Covid-19 virus and the emergence of new variants which are becoming more common these days.

“Additionally, the lifestyle aspect of wearing a mask becomes increasingly significant, as users seek to differentiate themselves through the masks they wear,” he said in a statement today.

With safety as the brand’s top priority, the masks have received certifications by the Medical Device Authority (MDA), the Conformite Europeene (CE) mark and ISO 13485:2016.

The masks are manufactured locally in Malaysia.

For a start, CommonMask will be available for online purchase via its website, https://commonmask.co.

The masks are scheduled to be made available at selected retail pharmacies and supermarkets at the end of September 2021.

In the near term, KIB targets to also commence the distribution of other healthcare-related products to expand the revenue streams under its new healthcare business.

The company has recently entered into a binding and conditional heads of agreement (HoA) with a UAE-based company to import and distribute the Hayat-Vax Covid-19 vaccines.

The Hayat-Vax vaccine is essentially the same Sinopharm Covid-19 vaccine, manufactured in UAE.

KIB has submitted the necessary applications to obtain the required approvals from the National Pharmaceutical Regulatory Agency (NPRA) for the Hayat-Vax vaccine to be used in Malaysia. 

Source: NST